Unicycive Therapeutics, Inc. last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.06. It usually reports 28–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Oct 27, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Oct 28, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 28–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-2
+73.3%
|
-0.06
+88.5%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-13
-2349.6%
|
-0.54
-8.0%
|
|
Oct 28, 2025
28 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-6
-46.8%
|
-0.33
+28.3%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-6
-165.4%
|
-0.52
+65.3%
|
|
May 14, 2025
44 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
1
+102.7%
|
-0.50
+18.0%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-4
+5.5%
|
-0.46
-253.8%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 13, 2024
43 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UNCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1766140
- Former names
- Unicycive Therapeutics, Inc. (until Oct 29, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.